Nantahala reports 4.84M shares (6.51%) of Opus Genetics
Opus Genetics, Inc. ownership disclosure: Nantahala Capital Management, LLC and related reporting persons report beneficial ownership of 4,839,225 shares of Common Stock as of March 31, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Opus Genetics, Inc. ownership disclosure: Nantahala Capital Management, LLC and related reporting persons report beneficial ownership of 4,839,225 shares of Common Stock as of March 31, 2026. The filing states that 3,157,895 of those shares may be acquired within sixty days through the exercise of convertible securities. Each of Nantahala, Wilmot B. Harkey and Daniel Mack is reported as beneficially owning 6.51% of the outstanding shares, with shared voting and dispositive power over the 4,839,225 shares.
Insights
Major shareholder reports shared control of 4.84M shares (6.51%).
The schedule states 4,839,225 shares are held by funds and accounts under Nantahala's control as of March 31, 2026, and that 3,157,895 shares are exercisable within sixty days via convertible securities. The filing attributes shared voting and dispositive power to Nantahala and to Messrs. Harkey and Mack as managing members.
Cash‑flow treatment and any planned dispositions are not described in the excerpt; subsequent filings would state transactions if they occur. Watch later public filings for changes to the reported stake or for Schedule 13D amendments if activist intent arises.
Disclosure aligns with adviser/control person reporting conventions.
The filing is an amended Schedule 13G/A identifying Nantahala as an investment adviser and Messrs. Harkey and Mack as control persons, and it attaches signatures including a Chief Compliance Officer. The statement that shares include convertible securities exercisable within sixty days is a standard beneficial‑ownership qualifier.
Confirmatory items to monitor in future filings include any change from passive 13G status to active 13D status or public trading by the reporting funds. Regulatory follow‑ups would appear in subsequent SEC schedules.
Key Figures
Key Terms
beneficial owner regulatory
convertible securities financial
Schedule 13G/A regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Nantahala Capital report in Opus Genetics (IRD)?
What is the filing date and form type for this ownership disclosure?
Who filed the Schedule 13G/A for Opus Genetics (IRD)?
AI-generated analysis. How Rhea-AI works. Not financial advice.